1.0SBI Pharmahttps://www.sbipharma.co.jp/en/rich600338<blockquote class="wp-embedded-content" data-secret="05JHD2Ixc5"><a href="https://www.sbipharma.co.jp/en/news/release/20210308/">Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.sbipharma.co.jp/en/news/release/20210308/embed/#?secret=05JHD2Ixc5" width="600" height="338" title="“Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals” — SBI Pharma" data-secret="05JHD2Ixc5" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.sbipharma.co.jp/wp-includes/js/wp-embed.min.js </script> SBI Pharmaceuticals Co., Ltd., and the University of Oxford in the United Kingdom hereby announce that the University of Oxford has  initiated a dose-finding Phase II clinical trial [Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study] to develop a cardioprotective agent combining 5-ALA hydrochloride and Sodium ferrous citrate for the mitigation of ischemia-reperfusion injury in response to cardiac surgery under cardiopulmonary bypass under the terms of the clinical trial sponsorship agreement between the two parties. The first patient has been dosed at the John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust.https://www.sbipharma.co.jp/wp-content/uploads/2020/02/SBI_HP-Image1_A_1.jpg1280550